文献速递流行病学与生物统计临床试验与 GCP

强化血压控制与标准血压控制对心血管及肾脏结局的获益-危害权衡:随机对照试验的个体参与者数据分析

Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2025-08-31

该研究是对六项随机对照试验(ACCORD BP、SPRINT、ESPRIT、BPROAD、STEP、CRHCP)的事后汇总个体参与者数据分析,共纳入80 220例参与者(强化组40 503例,标准组39 717例)。中位随访3.2年,强化血压控制组复合心血管疾病结局发生率为5.3%,标准组为7.1%(HR 0.76,95%CrI 0.72-0.81;p<0.0001)。强化组心血管疾病绝对风险降低1.73%(95%CrI 1.65-1.81;需治疗人数58),关注的不良事件绝对风险增加1.82%(95%CrI 1.63-2.01;需伤害人数55),净获益为1.14(95%CrI 1.03-1.25)。

要点

  • 强化血压控制较标准控制降低复合心血管疾病风险(HR 0.76,95%CrI 0.72-0.81)。
  • 强化组心血管绝对风险降低1.73%,关注的不良事件绝对风险增加1.82%。
  • 总体净获益为1.14(95%CrI 1.03-1.25),考虑肾脏相关不良事件时净获益仍为正(1.13)。

核心结论

  • 与标准血压控制相比,强化血压控制在心血管事件减少与不良事件(包括肾脏事件)增加之间提供净获益。

研究设计与样本

  • 事后汇总个体参与者数据分析,纳入六项随机对照试验(ACCORD BP、SPRINT、ESPRIT、BPROAD、STEP、CRHCP),初始数据集80 676例,分析纳入80 220例(强化组40 503例,标准组39 717例)。
  • 试验选择基于协作框架血压降低联盟-标志性证据及针对性文献检索,遵循五项预设纳入标准:比较强化收缩压目标(<120 mm Hg或<130 mm Hg)与标准治疗;报告复合主要心血管结局;入组超过2000例参与者;标准化报告治疗相关不良事件;可获得个体参与者数据。
  • 系统检索PubMed从数据库建立至2025年6月15日,无语言限制;十名评审员成对独立筛选和提取数据,分歧通过讨论或裁决解决。
  • 参与者随机分配至强化血压治疗(收缩压目标<120 mm Hg或<130 mm Hg)或标准治疗(收缩压目标<140 mm Hg,老年人<150 mm Hg,或常规护理),取决于试验设计。
  • 统计分析按意向性治疗原则,使用贝叶斯分层模型。

主要发现

  • 中位年龄64.0岁(IQR 59.0-70.0),男性39 043例(48.7%),女性41 177例(51.3%);大多数参与者为亚洲人(66 290例[82.6%])或白人(8097例[10.1%])。
  • 中位随访3.2年(IQR 3.0-3.5),复合心血管疾病结局在强化组发生2158例(5.3%),标准组2811例(7.1%)(HR 0.76,95%CrI 0.72-0.81;p<0.0001)。
  • 与标准血压控制相比,强化血压控制与心血管疾病绝对风险降低1.73%(95%CrI 1.65-1.81;需治疗人数58[95%CrI 55-61])相关,关注的不良事件绝对风险增加1.82%(95%CrI 1.63-2.01;需伤害人数55[95%CrI 49-61])。
  • 总体而言,强化血压控制显示有利的获益-危害特征,采用裁定权重时净获益为1.14(95%CrI 1.03-1.25)。
  • 考虑肾脏相关不良事件时,净获益仍为正(1.13[95%CrI 1.01-1.24])。

关键数值与推荐

  • 强化血压控制组复合心血管疾病结局发生率5.3%,标准组7.1%(HR 0.76,95%CrI 0.72-0.81;p<0.0001)。
  • 强化组心血管疾病绝对风险降低1.73%(95%CrI 1.65-1.81),需治疗人数58(95%CrI 55-61)。
  • 强化组关注的不良事件绝对风险增加1.82%(95%CrI 1.63-2.01),需伤害人数55(95%CrI 49-61)。
  • 净获益1.14(95%CrI 1.03-1.25);考虑肾脏相关不良事件时净获益1.13(95%CrI 1.01-1.24)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although intensive blood pressure control is recommended by major guidelines, its overall benefit-harm balance remains uncertain. In particular, it is unclear how net clinical benefit varies by blood pressure target and patient characteristics. We aimed to quantify the benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control. METHODS: We conducted a post-hoc, pooled participant-level analysis of six randomised controlled trials (ACCORD BP, SPRINT, ESPRIT, BPROAD, STEP, and CRHCP). Trial selection was based on our collaborative framework, the Blood Pressure Reduction Union-Landmark Evidence, and a targeted literature search, guided by five predefined inclusion criteria: (1) comparison of intensive systolic blood pressure targets (<120 mm Hg or <130 mm Hg) versus standard treatment; (2) reporting of composite major cardiovascular outcomes; (3) enrolment of more than 2000 participants; (4) standardised reporting of treatment-related adverse events; and (5) availability of individual participant data. We also conducted a systematic review in which we searched PubMed for studies published from database inception up to June 15, 2025, with no language restrictions. We used search terms related to cardiovascular outcomes, hypertension, intensive blood pressure lowering, and randomised trials. Study screening and data extraction were independently conducted in pairs by ten reviewers, with discrepancies resolved by discussion or adjudication. Participants in the six trials were randomly assigned to intensive blood pressure treatment (systolic blood pressure target <120 mm Hg or <130 mm Hg) versus standard treatment (systolic blood pressure target <140 mm Hg, <150 mm Hg in older adults, or usual care), depending on the trial design. The primary benefit outcome was a composite of myocardial infarction, stroke, heart failure, and cardiovascular death. The primary harm outcomes were adverse events of interest (eg, hypotension and syncope) and renal-related events. Statistical analyses were performed on an intention-to-treat basis using Bayesian hierarchical models. FINDINGS: The initial dataset included 80 676 participants, of whom 80 220 were included in our analyses (intensive blood pressure control group n=40 503; standard blood pressure control group n=39 717). The median age was 64·0 years (IQR 59·0-70·0), 39 043 (48·7%) participants were male, and 41 177 (51·3%) were female. Most participants were Asian (66 290 [82·6%]) or White (8097 [10·1%]). During a median follow-up of 3·2 years (IQR 3·0-3·5), the composite cardiovascular disease outcome occurred in 2158 (5·3%) participants in the intensive blood pressure control group and 2811 (7·1%) participants in the standard blood pressure control group (hazard ratio 0·76, 95% credible interval [CrI] 0·72-0·81; p<0·0001). Compared with standard blood pressure control, intensive blood pressure control was associated with a 1·73% absolute risk reduction (95% CrI 1·65-1·81) in cardiovascular disease (number needed to treat 58 [95% CrI 55-61]) and a 1·82% absolute risk increase (95% CrI 1·63-2·01) for adverse events of interest (number needed to harm 55 [95% CrI 49-61]). Overall, intensive blood pressure control showed a favourable benefit-harm profile, with a net benefit of 1·14 (95% CrI 1·03-1·25), using adjudicated weighting. The net benefit remained positive when considering kidney-related adverse events (1·13 [95% CrI 1·01-1·24]). INTERPRETATION: Compared with standard blood pressure control, intensive blood pressure control provides a net benefit between the reduction in cardiovascular events and the increase in adverse events, including renal events. FUNDING: National Key Research and Development Program, the Ministry of Science and Technology of China; National Science and Technology Major Project; National Natural Science Foundation of China; China Academy of Chinese Medical Sciences Innovation Fund for Medical Science; and Science and Technology Program of Liaoning Province.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Guo X, Sun G, Xu Y, et al. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials. Lancet. 2025. PMID: 40902616. doi:10.1016/S0140-6736(25)01391-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。